CervoMed Inc. (CRVO) has selected a 50 mg three‑times‑daily (TID) dosing regimen of a newly manufactured, stable crystal form of its lead candidate neflamapimod for the company’s planned Phase 3 study in dementia with Lewy bodies (DLB). The decision follows a Phase 1 healthy‑volunteer study that confirmed the pharmacokinetic profile of the stable crystal form closely matches the clinically active batch (Batch B) used in the Phase 2b RewinD‑LB extension, while the new formulation eliminates the polymorphic instability that had caused under‑dosing in earlier batches.
The stable crystal form addresses the polymorphic instability that previously led to under‑dosing, ensuring consistent drug exposure. The 50 mg TID dose is designed to achieve the plasma concentrations observed with Batch B, the formulation that produced the therapeutic exposure in the Phase 2b trial. By matching these concentrations, CervoMed aims to replicate the significant clinical and biomarker benefits seen in the extension study.
The Phase 2b RewinD‑LB extension reported a 54 % risk reduction in clinical progression and an 18 pg/mL reduction in plasma GFAP. Replicating these outcomes in a larger Phase 3 trial is a key objective, and the new formulation and dosing strategy are intended to provide the necessary exposure to achieve similar efficacy signals.
CervoMed’s Phase 3 initiation is scheduled for the second half of 2026, but it remains contingent on securing additional funding. As of September 30 2025, the company held $27.3 million in cash, cash equivalents, and marketable securities, and it faces substantial doubt about its ability to continue as a going concern without further capital. The company has not disclosed specific funding plans or a timeline for raising the required capital.
"The process historically used to manufacture neflamapimod produced drug substance containing multiple solid‑state forms, also called polymorphs. With prolonged storage, the less‑stable, higher‑solubility polymorphs converted into a more stable but lower‑solubility form, resulting in decreased bioavailability when administered to patients," said Marco Verwijs, Executive Vice President of Technical Operations. "By aligning plasma drug concentrations with those achieved from the clinically active DP Batch B capsules and incorporating a stable crystal form of neflamapimod that mitigates prior manufacturing challenges, we believe we are well positioned to replicate the positive clinical outcomes observed in the RewinD‑LB trial in our planned Phase 3 trial," added John Alam, MD, CEO.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.